Ubs Group Ag Cellectis S.A. Transaction History

Ubs Group Ag

$400 Billion
Q2 2024

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	SELL	$0.97 - $3.55 $3,816 - $13,969	-3,935 Reduced 97.52%	100 $0
Q3 2023 Nov 09, 2023	BUY	$1.58 - $2.86 $6,375 - $11,540	4,035 New	4,035 $6,000
Q1 2023 May 12, 2023	SELL	$1.83 - $3.84 $9,364 - $19,649	-5,117 Reduced 93.94%	330 $0
Q4 2022 Feb 08, 2023	BUY	$1.85 - $2.6 $2,849 - $4,004	1,540 Added 39.42%	5,447 $11,000
Q3 2022 Nov 10, 2022	BUY	$2.29 - $4.08 $8,044 - $14,333	3,513 Added 891.62%	3,907 $8,000
Q2 2022 Aug 10, 2022	SELL	$2.39 - $4.93 $5,673 - $11,703	-2,374 Reduced 85.77%	394 $1,000
Q1 2022 May 16, 2022	SELL	$3.45 - $8.77 $25,385 - $64,529	-7,358 Reduced 72.66%	2,768 $13,000
Q4 2021 Feb 14, 2022	SELL	$8.01 - $12.84 $49,469 - $79,299	-6,176 Reduced 37.88%	10,126 $82,000
Q3 2021 Nov 15, 2021	BUY	$11.94 - $16.09 $18,984 - $25,583	1,590 Added 10.81%	16,302 $206,000
Q2 2021 Aug 13, 2021	SELL	$14.36 - $20.93 $839,456 - $1.22 Million	-58,458 Reduced 79.89%	14,712 $227,000
Q1 2021 May 12, 2021	BUY	$18.19 - $33.25 $110,049 - $201,162	6,050 Added 9.01%	73,170 $1.48 Million
Q4 2020 Feb 11, 2021	SELL	$15.87 - $31.64 $181,648 - $362,151	-11,446 Reduced 14.57%	67,120 $1.82 Million
Q3 2020 Nov 12, 2020	BUY	$15.7 - $20.84 $924,478 - $1.23 Million	58,884 Added 299.18%	78,566 $1.45 Million
Q2 2020 Jul 31, 2020	SELL	$8.21 - $21.02 $88,158 - $225,712	-10,738 Reduced 35.3%	19,682 $350,000
Q1 2020 May 01, 2020	BUY	$7.81 - $18.82 $77,756 - $187,371	9,956 Added 48.65%	30,420 $280,000
Q4 2019 Feb 14, 2020	SELL	$9.73 - $19.31 $117,723 - $233,631	-12,099 Reduced 37.16%	20,464 $350,000
Q3 2019 Nov 14, 2019	SELL	$10.15 - $16.89 $54,272 - $90,310	-5,347 Reduced 14.1%	32,563 $339,000
Q2 2019 Aug 14, 2019	BUY	$14.6 - $20.6 $33,346 - $47,050	2,284 Added 6.41%	37,910 $591,000
Q1 2019 May 14, 2019	SELL	$15.53 - $19.75 $53,935 - $68,591	-3,473 Reduced 8.88%	35,626 $653,000
Q4 2018 Feb 14, 2019	SELL	$15.58 - $28.41 $439,667 - $801,730	-28,220 Reduced 41.92%	39,099 $651,000
Q3 2018 Nov 14, 2018	BUY	$25.99 - $30.6 $415,762 - $489,508	15,997 Added 31.17%	67,319 $1.9 Million
Q2 2018 Aug 14, 2018	BUY	$27.78 - $38.53 $998,385 - $1.38 Million	35,939 Added 233.63%	51,322 $1.45 Million
Q1 2018 May 15, 2018	BUY	$27.78 - $35.19 $251,520 - $318,610	9,054 Added 143.06%	15,383 $485,000
Q4 2017 Feb 14, 2018	SELL	$23.33 - $35.01 $62,314 - $93,511	-2,671 Reduced 29.68%	6,329 $185,000
Q3 2017 Nov 14, 2017	BUY	$21.65 - $32.18 $27,906 - $41,480	1,289 Added 16.72%	9,000 $257,000
Q2 2017 Aug 14, 2017	SELL	N/A	-179 Reduced 2.27%	7,711 $200,000
Q1 2017 Nov 14, 2017	BUY	N/A	7,890	7,890 $189,000

Others Institutions Holding CLLS

# of Institutions

Shares Held

11.2M

Call Options Held

2.8K

Put Options Held

17.9K

Long Focus Capital Management, LLC San Juan, PR

4.62M
Shares

$9.14 Million
0.35% of portfolio
Capital International Investors Los Angeles, CA

1.85M
Shares

$3.66 Million
0.0% of portfolio
Credit Suisse Ag Zurich, V8

1.44M
Shares

$2.85 Million
0.0% of portfolio
Ubs Asset Management Americas Inc Chicago, IL

1.44M
Shares

$2.85 Million
0.0% of portfolio
Baillie Gifford & CO

708K
Shares

$1.4 Million
0.0% of portfolio

View Full List

About Cellectis S.A.

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $90.1M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

More about CLLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account